$287 Million is the total value of COMMODORE CAPITAL LP's 29 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 25.8% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ACRS | Buy | ACLARIS THERAPEUTICS INC | $29,307,000 | +13.1% | 1,668,987 | +62.3% | 10.21% | -1.1% |
STSA | Buy | SATSUMA PHARMACEUTICALS INC | $21,832,000 | +51.9% | 3,096,729 | +27.3% | 7.61% | +32.9% |
CELC | New | CELCUITY INC | $20,903,000 | – | 870,967 | +100.0% | 7.28% | – |
CCCC | C4 THERAPEUTICS INC | $18,205,000 | +2.3% | 481,094 | 0.0% | 6.34% | -10.5% | |
CBAY | Buy | CYMABAY THERAPEUTICS INC | $15,388,000 | +13.6% | 3,529,465 | +18.3% | 5.36% | -0.6% |
CNST | Buy | CONSTELLATION PHARMCETICLS I | $14,901,000 | +72.9% | 440,869 | +19.7% | 5.19% | +51.2% |
CYTK | New | CYTOKINETICS INC | $13,938,000 | – | 704,317 | +100.0% | 4.86% | – |
KURA | Buy | KURA ONCOLOGY INC | $12,958,000 | -12.1% | 621,493 | +19.2% | 4.52% | -23.1% |
COGT | Buy | COGENT BIOSCIENCES INC | $11,091,000 | -0.5% | 1,367,582 | +7.8% | 3.86% | -13.0% |
ISEE | Buy | IVERIC BIO INC | $11,031,000 | +3.2% | 1,748,241 | +1.1% | 3.84% | -9.7% |
CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $10,816,000 | +41.9% | 323,437 | -12.6% | 3.77% | +24.1% |
MGNX | Buy | MACROGENICS INC | $10,579,000 | +612.4% | 393,850 | +744.6% | 3.69% | +522.6% |
VTGN | Sell | VISTAGEN THERAPEUTICS INC | $10,494,000 | +32.1% | 3,331,315 | -10.7% | 3.66% | +15.5% |
PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $9,452,000 | +4.4% | 210,600 | -39.8% | 3.29% | -8.7% |
EPIX | Buy | ESSA PHARMA INC | $8,054,000 | +56.8% | 281,911 | +59.4% | 2.81% | +37.1% |
KRON | KRONOS BIO INC | $7,157,000 | -18.2% | 298,839 | 0.0% | 2.49% | -28.4% | |
GNCA | Buy | GENOCEA BIOSCIENCES INC | $6,855,000 | -11.9% | 2,929,447 | +2.0% | 2.39% | -23.0% |
MREO | Buy | MEREO BIOPHARMA GROUP PLCads | $6,529,000 | -5.4% | 2,059,729 | +0.5% | 2.28% | -17.3% |
DYN | Sell | DYNE THERAPEUTICS INC | $6,420,000 | -3.9% | 305,125 | -29.1% | 2.24% | -15.9% |
XENE | Buy | XENON PHARMACEUTICALS INC | $6,076,000 | +12.6% | 326,336 | +8.3% | 2.12% | -1.5% |
MRSN | MERSANA THERAPEUTICS INC | $5,829,000 | -16.1% | 429,228 | 0.0% | 2.03% | -26.6% | |
KALV | Buy | KALVISTA PHARMACEUTICALS INC | $5,431,000 | -1.4% | 226,671 | +5.7% | 1.89% | -13.8% |
PMVP | PMV PHARMACEUTICALS INC | $4,270,000 | +3.9% | 125,000 | 0.0% | 1.49% | -9.2% | |
IVA | INVENTIVA SAads | $3,581,000 | -7.3% | 262,658 | 0.0% | 1.25% | -18.9% | |
MCRB | Buy | SERES THERAPEUTICS INC | $3,469,000 | +19.3% | 145,453 | +2.9% | 1.21% | +4.3% |
New | CATABASIS PHARMACEUTICALS IN | $3,412,000 | – | 1,617,000 | +100.0% | 1.19% | – | |
VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $3,409,000 | +9.8% | 186,405 | +0.3% | 1.19% | -3.9% |
SBTX | SILVERBACK THERAPEUTICS INC | $3,001,000 | -29.2% | 97,143 | 0.0% | 1.05% | -38.0% | |
BLSA | BCLS ACQUISITION CORP | $2,633,000 | -0.4% | 250,000 | 0.0% | 0.92% | -12.9% | |
LSAQ | Exit | LIFESCI ACQUISITION II CORP | $0 | – | -100,000 | -100.0% | -0.40% | – |
SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -236,500 | -100.0% | -2.11% | – |
RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -161,565 | -100.0% | -2.27% | – |
Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -795,868 | -100.0% | -3.40% | – | |
FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -361,344 | -100.0% | -5.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-10-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
CELCUITY INC | 10 | Q3 2023 | 7.3% |
KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-03-21 |
13F-HR/A | 2024-02-14 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.